

Shimada M, Miyagawa T, Toyoda H, Tokunaga K, and Honda M. (2018) "Epigenome-wide association study of DNA methylation in narcolepsy: an integrated genetic and epigenetic approach." *Sleep* 41:zsy019

Toyoda H, et al. (2017) "Narcolepsy susceptibility gene CCR3 modulates sleep-wake patterns in mice." **PLoS ONE** 12:e0187888

Miyata R, Hayashi M, Kohyama J, and Honda M.(2017) "Steroid therapy ameliorated cataplexy in three children with recent-onset of narcolepsy." *Sleep Med.* 29:86-87.

Tanaka S, Honda Y, Honda M, Yamada H, Honda K, and Kodama T. (2017) "Anti-tribbles pseudokinase 2 (TRIB2)-immunization modulate Hypocretin/Orexin neuronal functions." *Sleep* 40:zsw036.

Miyagawa T, et al. (2015) "New susceptibility variants to narcolepsy identified in HLA class II region." *Hum. Mol. Genet.* 24:891-898.

Miyagawa T, et al. (2013) "Effects of oral L- carnitine administration in narcolepsy patients: a randomized, double-blind, cross-over and placebocontrolled trial." **PLoS ONE** 8:e53707.

Miyagawa T, et al. (2011) "Abnormally low serum acylcarnitine levels in narcolepsy patients." *Sleep* 34:349-353.

Tanaka S, Honda M (2010) "IgG abnormality in narcolepsy and idiopathic hypersomnia." *PLoS ONE* 5: e955.

Toyoda H, et al. (2010) "Anti-tribbles homolog 2 autoantibodies in Japanese patients with narcolepsy." *Sleep* 33:875-878.

Honda M, et al. (2009) "IGFBP3 colocalizes with and regulates hypocretin(orexin)." *PLoS ONE* 4:e4254.

Honda M, Arai T, et al. (2009) "Absence of ubiquitinated inclusions in hypocretin neurons of narcolepsy patients." *Neurology* 73:511-517.

Tanaka S, Honda Y, Inoue Y, and Honda M. (2006) "Detection of autoantibodies against hypocretin, hcrtrl, and hcrtr2 in narcolepsy: anti-Hcrt system antibody in narcolepsy." *Sleep* 29:633-638.

Project Leader Makoto Honda Sleep Disorders Project


Narcolepsy and Hypersomnia: Find the causes to develop better treatments

Narcolepsy is a sleep disorder with abnormal intrinsic sleep-wake regulation, resulting in unique symptoms including frequent lapses into sleep, nocturnal sleep instability and REM sleep related manifestations such as cataplexy (abrupt loss of muscle tone triggered by emotion), sleep paralysis and hypnagogic hallucination.

Narcolepsy is associated with a deficiency of wake-promoting orexin/ hypocretin producing neurons localized in hypothalamus, and virtually all the patients carry *human leukocyte antigen (HLA)-DQB1*06:02.*

"We are trying to solve the mystery of narcolepsy: Listen to the patients, get the whole picture, and improve their lives"

Narcolepsy is associated with a variety of physical and psychiatric comorbid conditions. Since appropriate wakefulness is essential for higher brain functions, abnormal sleep-wake regulation can lead to various associated features. Despite the progress in sleep research fields, we currently have inadequate symptom-based-treatments for sleep disorders, including narcolepsy. We are trying to elucidate the pathophysiology of narcolepsy with multifaceted problems to improve the QOL of hypersomnia patients.




Research Interests

Hypothalamus works as a center for sleep-wake switch in coordination with the integrated information from the body. Among them, we have particular interests in immune and metabolic status, which can be the key to understand altered sleep-wake regulation in narcolepsy.

1. HLA association and immune abnormality

In addition to the tight association with HLA, narcolepsy is also associated with T cell receptor (TCR) alpha locus, indicating the HLA-TCR mediated immunological alterations. Both genetic and environmental factors are implicated in narcolepsy predisposition. We have reported the altered immune status in narcolepsy, but so far could not confirm the leading hypothesis that orexin neurons are destructed by direct autoimmune attacks. Immune mechanisms other than autoimmunity might lead to stop producing orexin neuropeptide.



2. Metabolic aspect of narcolepsy and related hypersomnia

Through genome-wide association studies (GWAS), we have identified novel narcolepsy (and other hypersomnia) related genes. They are key enzymes located in the pathway of fatty acid metabolism. We confirmed their functional relevance, performed the clinical trials, and analyzing the potential efficacy of the novel therapy (promoting metabolism) in hypersomnia patients.

